Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled Study of Intranasal Midazolam (USL261) for Outpatient Treatment of Seizure Clusters
2011-001318-32Phase 3Terminated
- Sponsor
- Upsher-Smith Laboratories
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy comparing USL261 intranasal midazolam with Intranasal placebo (2 arms). Primary endpoint: Treatment Success. Started Aug 2011; status: terminated.
02
Drugs
ITI-111
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2011-001318-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001318-32.